Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital

Long-Term Safety of Treatment with Autologous Mesenchymal Stem Cells in Patients with Radiation-Induced Xerostomia: Primary Results of the MESRIX Phase I/II Randomized Trial

Publikation: Bidrag til tidsskriftTidsskriftartikelpeer review

  1. B Cells and Tertiary Lymphoid Structures: Friends or Foes in Cancer Immunotherapy?

    Publikation: Bidrag til tidsskriftReviewpeer review

  2. A Phase II Study of the Efficacy and Safety of Oral Selinexor in Recurrent Glioblastoma

    Publikation: Bidrag til tidsskriftTidsskriftartikelpeer review

  3. Clinical Outcomes in Patients with Multi-Hit TP53 Chronic Lymphocytic Leukemia Treated with Ibrutinib

    Publikation: Bidrag til tidsskriftTidsskriftartikelpeer review

  4. Detection of Molecular Signatures of Homologous Recombination Deficiency in Bladder Cancer

    Publikation: Bidrag til tidsskriftTidsskriftartikelpeer review

Vis graf over relationer

PURPOSE: Mesenchymal stem/stromal cell therapy may reduce radiation-induced xerostomia. We investigated the long-term safety of autologous adipose tissue-derived mesenchymal stem/stromal cell (ASC) injections into the submandibular glands.

EXPERIMENTAL DESIGN: An investigator-initiated, randomized, single-center, placebo-controlled trial. Previous patients with oropharyngeal squamous cell carcinoma with radiation-induced xerostomia were randomly (1:1) allocated to receive a 2.8 million ASCs/cm3 injection or placebo in both submandibular glands and followed for a minimum of 2 years. The primary endpoint was number of serious adverse events (SAE). Secondary endpoints included whole saliva flow rates and xerostomia-related symptoms. Data analysis was based on the intention-to-treat population using repeated measures mixed-effects linear models.

RESULTS: Thirty-three patients were randomized; 30 patients were treated (ASC group, n = 15; placebo group, n = 15). Long-term safety data were collected from all 30 patients. During follow-up, 6 of 15 (40%) of the ASC-treated patients versus 5 of 15 (33%) of the placebo patients experienced an SAE; no SAEs appeared to be treatment related. Unstimulated whole saliva flow rate increased to 0.20 and 0.16 mL/minute in the ASC and placebo group, respectively, yielding a 0.05 mL/minute (95% confidence interval: 0.00-0.10; P = 0.051) difference between groups. Patient-reported xerostomia symptoms diminished according to a decreased xerostomia questionnaire summary score of 35.0 and 45.1, respectively [-10.1 (-18.1 to -2.2); P = 0.013]. Three of the visual analog scale xerostomia measures indicated clinical benefit following use of ASC.

CONCLUSIONS: Our data show that ASC therapy is safe with a clinically relevant effect on xerostomia-related symptoms. Confirmation in larger randomized controlled trials is warranted.

TidsskriftClinical Cancer Research
Udgave nummer13
Sider (fra-til)2890-2897
Antal sider8
StatusUdgivet - 1 jul. 2022

ID: 77811907